The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Apr. 05, 2022
Filed:
Mar. 18, 2019
Applicant:
Biogen MA Inc., Cambridge, MA (US);
Inventor:
Ivan Lieberburg, Berkeley, CA (US);
Assignee:
Biogen MA Inc., Cambridge, MA (US);
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 39/395 (2006.01); C07K 16/28 (2006.01); G01N 33/68 (2006.01); A61K 38/03 (2006.01); A61K 38/21 (2006.01); A61K 45/06 (2006.01); A61K 49/00 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
C07K 16/2839 (2013.01); A61K 38/03 (2013.01); A61K 38/215 (2013.01); A61K 39/3955 (2013.01); A61K 39/39541 (2013.01); A61K 45/06 (2013.01); A61K 49/0004 (2013.01); C07K 16/2842 (2013.01); G01N 33/6893 (2013.01); G01N 33/6896 (2013.01); A61K 2039/505 (2013.01); A61K 2039/54 (2013.01); A61K 2039/545 (2013.01); C07K 2317/24 (2013.01); G01N 2333/025 (2013.01); G01N 2800/065 (2013.01); G01N 2800/285 (2013.01); G01N 2800/7095 (2013.01); Y02A 50/30 (2018.01);
Abstract
Natalizumab is a safe and efficacious treatment for inflammatory and autoimmune diseases, such as multiple sclerosis, Crohn's Disease, and rheumatoid arthritis. Rare occurrences of progressive multifocal leucoencephalopathy during treatment suggest the possibility that it may be related to natalizumab treatment. Monitoring for JCV and informing caregivers and patients about the manifestations of progressive multifocal leucoencephalopathy can improve the safety of natalizumab therapy.